⚠️ Teaching Case Note: This case has been de-identified and reconstructed for educational purposes. Clinical details reflect real surgical decision-making and outcomes. Patient identity is fully protected.
HbA1c 9.2%, Triglycerides 18.5, Liver Fibrosis, Undiagnosed Thyroid Disease — Five Diagnoses, One Coordinated Plan, Reversed at One Year
He was 42 years old, American, a senior executive based in Shanghai. He had been on three diabetes medications for five years and his blood sugar was still out of control. His triglycerides came back at 18.5 mmol/L — more than ten times the upper limit of normal, and high enough to trigger acute pancreatitis without warning. His liver showed Stage F3 fibrosis on FibroScan. His thyroid was underactive and nobody had treated it. His BMI was 31.2.
Dr. Weiqing Wang's team at Ruijin Hospital, Shanghai Jiao Tong University, did not treat five problems separately. They identified the common metabolic substrate driving all of them — severe insulin resistance compounded by subclinical hypothyroidism and visceral obesity — and built a single coordinated intervention around it.
At one year: HbA1c was 6.2%. Triglycerides were in the normal range. Liver fibrosis had regressed from F3 to below the F2 threshold. The patient had lost 8 kg of predominantly visceral fat. His microalbuminuria had reversed. He was swimming three times a week.
The Presentation: Five Diagnoses, All Interconnected
The laboratory results told a coherent story once read as a system rather than a list. The C-peptide release test showed markedly elevated fasting and postprandial C-peptide — the patient was producing large amounts of insulin, but his tissues were not responding to it. This was not insulin deficiency. It was profound insulin resistance, and adding more insulin to the regimen — the conventional next step — would have worsened the obesity and the triglycerides without addressing the underlying mechanism.
The triglyceride level of 18.5 mmol/L was a medical emergency in slow motion. Above 10 mmol/L, the risk of acute hypertriglyceridemia-induced pancreatitis becomes clinically significant; above 20 mmol/L, it becomes high. The patient had no abdominal symptoms yet, but the trajectory was clear.
The FibroScan result — liver stiffness measurement of 12.5 kPa with a controlled attenuation parameter of 320 dB/m — indicated severe hepatic steatosis with Stage F3 fibrosis. At this stage, the liver is one step from cirrhosis. The conventional view that metabolic fatty liver disease requires no specific treatment was not applicable here.
TSH of 6.8 mIU/L with normal FT4 defined subclinical hypothyroidism — a condition that independently worsens insulin resistance, raises LDL cholesterol, and impairs triglyceride clearance. It had not been identified or treated in five years of diabetes management.
The right adrenal incidentaloma on CT was evaluated and confirmed as a non-functioning adenoma — no hormonal excess, no intervention required, surveillance imaging scheduled.
Complication screening completed the picture: UACR of 150 mg/g indicated early diabetic nephropathy; fundoscopy showed background retinopathy. The patient was 42 years old and already had end-organ involvement in two systems.
The Treatment Decision: Address the Root Mechanism, Not the Individual Numbers
The endocrinology team's assessment was that the patient's five diagnoses shared a common driver: severe insulin resistance amplified by visceral obesity, worsened by untreated hypothyroidism, and expressed as hyperglycemia, hypertriglyceridemia, hepatic steatosis, and early nephropathy simultaneously. Treating each abnormal number with a separate drug — the conventional polypharmacy approach — would have produced a complex regimen without addressing the mechanism.
The central pharmacological decision was to replace the basal insulin with a GLP-1 receptor agonist (semaglutide, weekly formulation). GLP-1 receptor agonists reduce blood glucose through glucose-dependent insulin secretion and glucagon suppression, reduce body weight through central appetite suppression and delayed gastric emptying, lower triglycerides through reduced hepatic VLDL synthesis, and have demonstrated cardiovascular outcome benefits in high-risk patients with Type 2 diabetes. For this patient's specific profile — insulin resistance dominant, obese, hypertriglyceridemic, with early cardiovascular risk factors — semaglutide addressed four of the five diagnoses through a single mechanism.
Fenofibrate was added immediately to reduce the triglyceride level below the acute pancreatitis threshold while semaglutide's lipid effects accumulated over weeks. Low-dose levothyroxine (25 mcg daily) was initiated to correct the subclinical hypothyroidism and remove its contribution to insulin resistance and dyslipidemia. High-purity omega-3 fatty acids were added as adjunctive triglyceride-lowering therapy. Metformin was continued. Basal insulin was stopped.
A continuous glucose monitor (CGM) was applied for two weeks to characterize the patient's glycemic pattern — identifying postprandial spikes driven by business dinner carbohydrate loads and nocturnal hypoglycemia from the previous insulin regimen — and to guide dietary counseling. The Ruijin Hospital medical nutrition program prescribed a low-carbohydrate, high-protein dietary structure compatible with the patient's travel and entertainment schedule.
Treatment Phases: From Emergency Stabilization to Long-Term Reversal
Phase one — acute intervention (inpatient, 2 weeks). Fenofibrate and ezetimibe were started immediately. Within seven days, triglycerides had fallen from 18.5 to 8.0 mmol/L — below the acute pancreatitis high-risk threshold. Semaglutide was initiated at the starting dose. Fasting glucose stabilized at 6.5–7.0 mmol/L without hypoglycemia. The patient reported reduced appetite and spontaneously decreased meal portions within the first week — the expected central satiety effect of GLP-1 receptor agonism.
Phase two — dose titration and metabolic stabilization (months 1–3). Semaglutide was uptitrated every two weeks to the target dose of 1.0 mg weekly. Levothyroxine was adjusted to bring TSH to 3.0 mIU/L. At three months: HbA1c had fallen from 9.2% to 6.8%. Triglycerides were 3.5 mmol/L. Body weight had decreased by 8 kg, predominantly visceral fat as confirmed by waist circumference reduction. Repeat FibroScan showed liver stiffness measurement reduced from 12.5 to 9.0 kPa — regression of hepatic fibrosis by one stage.
Phase three — long-term maintenance and digital management (months 6–12). The regimen was simplified: fenofibrate was discontinued as triglycerides had normalized; the final maintenance regimen was semaglutide, metformin, and a statin. The patient enrolled in Ruijin Hospital's internet hospital platform, uploading CGM data and blood pressure readings for remote review by Dr. Wang's team, with medication adjustments made without requiring in-person visits — a critical feature for a patient with an international travel schedule.
Outcomes at One Year
HbA1c: 6.2–6.5%, stable. Fasting glucose: 5.8–6.2 mmol/L. Triglycerides: within normal range. LDL-C: at target on statin therapy. Body weight: BMI reduced from 31.2 to 28.5 kg/m². UACR: reduced from 150 to 30 mg/g — microalbuminuria reversed, early nephropathy stabilized. Liver stiffness: below the F2 fibrosis threshold on repeat FibroScan — a clinically meaningful regression in a condition previously considered largely irreversible without bariatric surgery. The patient was exercising regularly — swimming and resistance training three times per week — and had restructured his business dinner habits around the dietary framework established during the Ruijin admission.
Expert Commentary — Dr. Weiqing Wang
"This patient had been treated for diabetes for five years without anyone asking why his insulin resistance was so severe, why his triglycerides were so high, or why his liver was fibrotic. Each abnormality had been noted and filed. None had been connected to the others or traced to a common mechanism.
The subclinical hypothyroidism is the clearest example. A TSH of 6.8 in a patient with severe insulin resistance, hypertriglyceridemia, and obesity is not an incidental finding — it is a contributing cause. Hypothyroidism reduces lipoprotein lipase activity, impairing triglyceride clearance. It reduces hepatic LDL receptor expression, raising LDL. It worsens insulin sensitivity directly. Twenty-five micrograms of levothyroxine daily addressed all three of these effects simultaneously. It cost almost nothing. It had not been prescribed in five years of diabetes management because no one had checked the TSH.
The GLP-1 receptor agonist decision was not complicated once the mechanism was clear. This patient had insulin resistance, not insulin deficiency. Adding more insulin — the conventional escalation — would have driven further weight gain, worsened the triglycerides through increased hepatic lipogenesis, and deepened the resistance. Semaglutide works through a different mechanism entirely: it reduces the demand on the insulin system rather than increasing the supply. For a patient whose C-peptide showed he was already producing excess insulin, that distinction is the entire treatment.
The liver fibrosis regression is the outcome I am most satisfied with. Stage F3 fibrosis in a 42-year-old is a trajectory toward cirrhosis within a decade if untreated. The conventional view — that metabolic fatty liver disease is managed by treating the diabetes and hoping the liver improves — is not wrong, but it is not sufficient. You have to treat the liver as a target organ in its own right, monitor it with FibroScan, and set fibrosis regression as an explicit treatment goal. We achieved it in twelve months. That changes this patient's long-term prognosis fundamentally."
About Dr. Weiqing Wang
Dr. Weiqing Wang is Director of the Endocrinology Department at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, and a nationally recognized authority on diabetes management, thyroid disease, and adrenal disorders. She leads China's largest endocrine clinical research center and has extensive experience treating complex metabolic conditions in international patients. Dr. Wang is a standing committee member of the Chinese Diabetes Society and has led multiple national and international multicenter clinical trials in metabolic disease.
How CMCS Supported This Patient
China Medical Concierge – Shanghai (CMCS) coordinated the full care pathway for this American executive: specialist matching and priority access to Dr. Wang's team at Ruijin Hospital, coordination of the comprehensive metabolic workup — including FibroScan, adrenal CT, CGM setup, and complication screening — across multiple departments in a single admission, full English-language communication throughout including laboratory result interpretation, medication counseling, and dietary program explanation, international insurance coordination and documentation, and ongoing remote follow-up support including CGM data review scheduling and liaison between Dr. Wang's team and the patient's primary care physician in the United States.
For international patients and expatriates in Shanghai managing complex metabolic conditions — where the integration of endocrinology, hepatology, cardiology risk management, and digital chronic disease monitoring determines long-term outcomes — CMCS provides end-to-end support from initial workup to annual review and international care coordination.
📧 contract@medicalsh.com | 📱 WhatsApp | 🌐 medicalsh.com
0 comentarios